key: cord-0900353-820zjhtz authors: O’Donnell, Kyle L.; Pinski, Amanda N.; Clancy, Chad S.; Gourdine, Tylisha; Shifflett, Kyle; Fletcher, Paige; Messaoudi, Ilhem; Marzi, Andrea title: Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model date: 2021-07-12 journal: bioRxiv DOI: 10.1101/2021.07.11.451964 sha: 694a8cd9f0ccf1670fac60b715a4a8aecf82ce5e doc_id: 900353 cord_uid: 820zjhtz Following the discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its rapid spread throughout the world, new viral variants of concern (VOC) have emerged. There is a critical need to understand the impact of the emerging variants on host response and disease dynamics to facilitate the development of vaccines and therapeutics. Syrian golden hamsters are the leading small animal model that recapitulates key aspects of severe coronavirus disease 2019 (COVID-19). In this study, we show that intranasal inoculation of SARS-CoV-2 into hamsters with the ancestral virus (nCoV-WA1–2020) or VOC first identified in the United Kingdom (B.1.1.7) and South Africa (B.1.351) led to similar gross and histopathologic pulmonary lesions. Although differences in viral genomic copy numbers were noted in the lungs and oral swabs of challenged animals, infectious titers in the lungs were comparable. Antibody neutralization capacities varied, dependent on the original challenge virus and cross-variant protective capacity. Transcriptional profiling indicated significant induction of antiviral pathways in response to all three challenges with a more robust inflammatory signature in response to B.1.1.7. Furthermore, no additional mutations in the spike protein were detected at peak disease. In conclusion, the emerging VOC showed distinct humoral responses and transcriptional profiles in the hamster model compared to the ancestral virus. and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. ; https://doi.org/10.1101/2021.07.11.451964 doi: bioRxiv preprint ORF3a, both of which have been implicated in evasion of type I IFN 27, 28 . A second mutation in 245 nsp3 was also identified in a single B.1.351-infected animal. The implication of these mutations 246 remains to be elucidated. 247 Analysis of the humoral response revealed that the overall IgG response of the infected 248 hamsters did not result in robust differences amongst the variants; however, the neutralization 249 cross-protection depended on the variant the hamster was initially exposed to. Specifically, 250 infection with B.1.1.7 results in the widest breath of neutralization activity despite comparable 251 binding antibody titers. This phenomenon was most noticeable at 14 DPC, and was still evident 252 28 DPC when the humoral response is more mature. Moreover, the overall neutralization 253 activity, regardless of initial challenge virus, against B.1.351 is much lower than the other two 254 variants, suggesting that B.1.351 may have indeed an enhanced ability to evade humoral 255 immune responses. The overall IgG response of the infected hamsters did not result in robust 256 differences amongst the variants; however, the neutralization cross-protection depended on 257 the variant the hamster was initially exposed to. Our data demonstrates that early in the 258 humoral response (14 DPC) antibodies induced by B.1.1.7 infection show an increased 259 crossrreacitvity compared to the other variants tested. By 28 DPC, when the humoral response 260 is more mature, this differences is less prominent, but the trend remains the same. This 261 observation suggests that the timing of the antibody response could affect the crossreactivity 262 potential. Notably, the neutralization capacity of crossreactive antibodies and homologous 263 antibodies against B.1.351 is much lower than that of the other two variants tested. This 264 observation is reflective of previous studies that attribute increased antibody evasion to this 265 VOC 3,4,8-10,12,21,22 , demonstrating that the hamster model reflects the differences in humoral 266 responses and effectivity of prior immunity seen in clinical cases 29 . 267 A significant challenge when using the hamster model is the lack of reagents to analyze cellular 268 immune responses 30-36 . Therefore, we employed transcriptomic analysis to elucidate 269 differences in the host responses to VOC compared to the ancestral variant in the lungs of 270 hamster 4 DPC, as has been done for other studies 37-39 . Our transcriptional analysis of lung 271 tissues at peak infection identified distinct, but also overlapping transcriptional signatures for 272 each variant. All infections exhibited gene expression patterns associated with innate antiviral 273 and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. In this study we describe the pathogenesis of the SARS-CoV-2 variants and the development of 307 crossreactive neutralizing antibodies. To our knowledge this is the first study performing a 308 comparative and longitudinal analysis of the antibody response after SARS-CoV-2 VOC infection. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. ; https://doi.org/10.1101/2021.07.11.451964 doi: bioRxiv preprint and minimize animal suffering; food and water were available ad libitum. processed and RNA was extracted using the RNeasy Mini Kit (QIAGEN) according to 358 manufacturer specifications. One step RT-qPCR for genomic viral RNA was performed using 359 and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. The day before this assay, VeroE6 cells were seeded in 96-well plates. Serum samples were 382 heat-inactivated for 30 min at 56°C, and 2-fold serial dilutions were prepared in DMEM with 2% 383 FBS. Next, 100 TCID50 of SARS-CoV-2 were added and the mixture was incubated for 1 hour at 384 37°C and 5% CO2. Finally, media was removed from cells and the mixture was added to VeroE6 385 cells and incubated at 37°C and 5% CO2 for 6 days. Then the cytopathic effect (CPE) was 386 documented, and the virus neutralization titer was expressed as the reciprocal value of the 387 highest dilution of the serum which inhibited virus replication (no CPE). 388 and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. ; https://doi.org/10.1101/2021.07.11.451964 doi: bioRxiv preprint Necropsies and tissue sampling were performed according to IBC-approved SOPs. Tissues were 391 fixed in 10% neutral buffered formalin with two changes, for a minimum of 7 days. Tissues were 392 placed in cassettes and processed with a Sakura VIP-6 Tissue Tek, on a 12-hour automated 393 schedule, using a graded series of ethanol, xylene, and ParaPlast Extra. and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. EPI_ISL_6786156. All genomes had greater than 95% coverage and 10X depth. Single nucleotide 445 polymorphisms and amino acid changes were identified using CorGAT. 446 and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. ; https://doi.org/10.1101/2021.07.11.451964 doi: bioRxiv preprint All statistical analysis was performed in Prism 8 (GraphPad). Two-tailed Mann-Whitney test was 449 conducted to compare differences between groups for data in Figs. 2, 3 and S1. Statistical 450 significance was determined using one-way ANOVA with multiple comparisons for the 451 bioinformatic analysis with comparisons made among variant-and control-challenged animals 452 Statistically significant differences are indicated as follows: p<0.0001 (****), p<0.001 (***), 453 p<0.01 (**) and p<0.05 (*). 454 455 456 and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. ; https://doi.org/10.1101/2021.07.11.451964 doi: bioRxiv preprint was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. ; https://doi.org/10.1101/2021.07.11.451964 doi: bioRxiv preprint and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. ; https://doi.org/10.1101/2021.07.11.451964 doi: bioRxiv preprint was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. ; https://doi.org/10.1101/2021.07.11.451964 doi: bioRxiv preprint and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. ; https://doi.org/10.1101/2021.07.11.451964 doi: bioRxiv preprint and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. ; https://doi.org/10.1101/2021.07.11.451964 doi: bioRxiv preprint and is also made available for use under a CC0 license. was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 The copyright holder for this preprint (which this version posted July 12, 2021. ; https://doi.org/10.1101/2021.07.11.451964 doi: bioRxiv preprint Novel Coronavirus (2019-nCoV) Pneumonia Science Brief: emerging SARS-CoV-2 variants Early transmissibility assessment of the N501Y 642 mutant strains of SARS-CoV-2 in the United Kingdom Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the 645 human ACE2 receptor: insights from molecular dynamics simulations Structural basis for enhanced infectivity and 648 immune evasion of SARS-CoV-2 variants Preliminary genomic characterisation of an emergent SARS-CoV-2 651 lineage in the UK defined by a novel set of spike mutations Genomic characterisation of an emergent SARS-CoV-2 lineage in 655 Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived 657 polyclonal antibodies Neutralizing Activity of BNT162b2-Elicited Serum SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma A novel coronavirus outbreak of global health concern Genomic characterisation of an emergent SARS-CoV-2 lineage in 665 Manaus: preliminary findings Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 669 infection Pathogenesis and transmission of SARS-CoV-2 in golden hamsters A contemporary view of coronavirus transcription Immune response in silico (IRIS): immune-specific genes identified from a compendium 677 of microarray expression data Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain 683 that Escape Antibody Recognition mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease Activation and evasion of type I interferon responses by SARS-CoV-2 Evasion of Type I Interferon by SARS-CoV-2 Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence A Syrian golden hamster model recapitulating ebola hemorrhagic fever Comparison of the pathogenicity of Nipah virus isolates from Bangladesh and 704 Malaysia in the Syrian hamster T cells are not required for pathogenesis in the Syrian hamster model 706 of hantavirus pulmonary syndrome The adaptive immune response does not influence hantavirus disease or persistence in 708 the Syrian hamster Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal 710 challenge with andes virus Hamster-adapted Sin Nombre virus causes disseminated infection and efficiently 712 replicates in pulmonary endothelial cells without signs of disease Validation of assays to monitor immune 715 responses in the Syrian golden hamster (Mesocricetus auratus) Characterization of the host response to pichinde virus infection in the Syrian golden 718 hamster by species-specific kinome analysis Sequencing, annotation and analysis of the Syrian hamster 721 (Mesocricetus auratus) transcriptome Transcriptome sequencing and development of 723 an expression microarray platform for liver infection in adenovirus type 5-infected Syrian golden 724 hamsters The Immune Response and 726 Immunopathology of COVID-19 Viral presence and immunopathology in patients with lethal COVID-19: a prospective 728 autopsy cohort study The role of dysregulated immune responses in COVID-19 pathogenesis Clinical Characteristics of 138 Hospitalized Patients With Interferons and viruses: an interplay between induction, signalling, antiviral 1488.e1412 Impaired type I interferon activity and inflammatory responses in severe COVID-19 742 patients Lung transcriptome of a COVID-19 patient and systems biology 744 predictions suggest impaired surfactant production which may be druggable by surfactant therapy Type I and III interferons disrupt lung epithelial repair during recovery from viral infection Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics in lungs of African 749 green monkeys Transcriptional and proteomic insights into the host response in fatal COVID-19 cases Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The 754 Clinical characteristics of 113 deceased patients with coronavirus disease 2019: 756 retrospective study Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control Clinical and immunological features of severe and moderate coronavirus disease 2019 Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 The Role and Therapeutic 765 Potential of NF-kappa-B Pathway in Severe COVID-19 Patients SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells 768 Elicits a Rapid Epithelial-Intrinsic Inflammatory Response COVID-19-neutralizing antibodies predict disease severity and survival A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between 773 neutralizing antibodies and COVID-19 severity Defining the features and duration of antibody responses to SARS-CoV-2 infection 776 associated with disease severity and outcome Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington 779 State: a case series Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus 781 Complement associated microvascular injury and thrombosis in the pathogenesis of 783 severe COVID-19 infection: A report of five cases Inactivation of SARS-CoV-2 Laboratory 786 Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus 788 ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques Metascape provides a biologist-oriented resource for the analysis of systems-level datasets